<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768157</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-HCC004</org_study_id>
    <nct_id>NCT00768157</nct_id>
  </id_info>
  <brief_title>Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma</brief_title>
  <official_title>Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most hepatocellular carcinomas are associated with hepatitis B virus, it is hypothesized that
      anti-viral treatment may be helpful in treating HBV-related hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As we know, recurrence and metastasis could happen in hepatocellular carcinoma even after
      radical resection.One reason is that virus hepatitis B could be one factor contributing to
      the carcinogenesis of hepatocellular carcinoma.To investigated whether anti-viral therapy
      could improve the efficacy of radical resection of hepatitis B virus (HBV)-related
      hepatocellular carcinoma(HCC),we planed to conduct this clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survivals</measure>
    <time_frame>2,3,5years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>2,3,5years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatitis B Virus</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>antiviral group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiviral treatment (lamivudine or entecavir)</intervention_name>
    <description>antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)</description>
    <arm_group_label>antiviral group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical resection of HBV-related HCC</intervention_name>
    <description>Procedure/Surgery - radical resection of HBV-related HCC</description>
    <arm_group_label>antiviral group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients who did not receive antiviral therapy prior to the resection of
             hepatocellular carcinoma

          2. patients who underwent radical resection of HCC, and 1 month after surgery,dynamic
             computed tomography showed on lesion in the liver and no signs of extrahepatic
             metastasis.

          3. hepatitis B surface antigen should be positive before surgery HBV-DNA level between
             100000 copies/ml and 10000000copies/ml anti-HCV negative

        Exclusion Criteria:

          1. previous history of antiviral therapy

          2. a baseline serum alanine aminotransferase level 2.5 times the ULN or higher

          3. positive for anti-HCV or anti-HIV

          4. Child-Pugh classification B or C after surgery

          5. preexisting evidence of hepatic decompensation, including encephalopathy,ascites,a
             bilirubin level more than 2 times the ULN, or a prolonged prothrombin time of more
             than 3 seconds

          6. signs showing recurrence or metastasis oen month after surgery

          7. underlying cardiac or renal diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Qing LI, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min-Shan CHEN, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiao-Jun LIN, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiang-Ming LAO, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang-Ming LAO, Ph.D</last_name>
    <phone>8620-87343115</phone>
    <email>laoxming@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Jun LIN, Ph.D</last_name>
    <phone>8620-87343017</phone>
    <email>sumslxm@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiang-Ming Lao</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang-Ming LAO, Ph.D</last_name>
      <phone>8620-87343017</phone>
      <email>laoxming@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jin-Qing LI, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Jun LIN, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min-Shan CHEN, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.com/</url>
    <description>Cancer Center of Sun Yat-sen University</description>
  </link>
  <reference>
    <citation>Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006 Feb;43(2):233-40.</citation>
    <PMID>16440357</PMID>
  </reference>
  <reference>
    <citation>Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM, Lee CD. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007 Oct 15;110(8):1760-7.</citation>
    <PMID>17724708</PMID>
  </reference>
  <reference>
    <citation>Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, Yang JM, Ahn BM, Lee CD, Lee YS, Chung KW, Sun HS. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004 Sep;41(3):427-35.</citation>
    <PMID>15336446</PMID>
  </reference>
  <reference>
    <citation>Poon RT. Significance of viral status on prognosis after resection of hepatitis B virus related hepatocellular carcinoma. J Hepatol. 2007 Nov;47(5):630-1. Epub 2007 Sep 5.</citation>
    <PMID>17881079</PMID>
  </reference>
  <reference>
    <citation>Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007 Nov;47(5):684-90. Epub 2007 Aug 13.</citation>
    <PMID>17854945</PMID>
  </reference>
  <reference>
    <citation>Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K, Nishiguchi S, Kinoshita H. Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg. 2002 May;26(5):555-60. Epub 2002 Feb 19.</citation>
    <PMID>12098045</PMID>
  </reference>
  <reference>
    <citation>Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto T, Kinoshita H, Kuroki T. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg. 2001 Jan;233(1):139-45.</citation>
    <PMID>11141236</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cancer Center of Sun Yat-sen University</name_title>
    <organization>Cancer Center of Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>surgery</keyword>
  <keyword>anti-virus</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

